Publications
Recent high-impact publications from Rogel Cancer Center members.
|
|
Publications from members of the Cancer Biology, Cancer Genetics, Cancer Hematopoiesis & Immunology, and Developmental Therapeutics programs
|
|
Mendez, F.; Kadiyala, P.; Nunez, F. J.; Carney, S.; Nunez, F. M.; Gauss, J. C.; Ravindran, R.; Pawar, S.; Edwards, M.; Garcia-Fabiani, M. B.; Haase, S.; Lowenstein, P. R.; Castro, M. G.
Therapeutic efficacy of immune stimulatory thymidine kinase and fms-like tyrosine kinase 3 ligand (TK/Flt3L) gene therapy in a mouse model of high grade brainstem glioma.
Clin Cancer Res
(2020)
In process.
PMID: 32332014.
Leonard, D.; Huang, W.; Izadmehr, S.; O'Connor, C. M.; Wiredja, D. D.; Wang, Z.; Zaware, N.; Chen, Y.; Schlatzer, D. M.; Kiselar, J.; Vasireddi, N.; Schuchner, S.; Perl, A. L.; Galsky, M. D.; Xu, W.; Brautigan, D. L.; Ogris, E.; Taylor, D. J.; Narla, G.
Selective PP2A Enhancement through Biased Heterotrimer Stabilization.
Cell
(2020)
In process.
PMID: 32315618.
Djomehri, S. I.; Gonzalez, M. E.; da Veiga Leprevost, F.; Tekula, S. R.; Chang, H. Y.; White, M. J.; Cimino-Mathews, A.; Burman, B.; Basrur, V.; Argani, P.; Nesvizhskii, A. I.; Kleer, C. G.
Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors.
Nat Commun
(2020) 11:1723. PMID: 32265444. PMCID: PMC7138853.
|
|
|
Senior study author Goutham Narla, M.D., Ph.D.
|
|
"Working together, we now have a story about being able to drug this previously undruggable tumor suppressor." -
Goutham Narla, M.D., Ph.D.
|
|
|
|
CANCER CONTROL AND POPULATION SCIENCES
|
|
Publications from members of the Cancer Epidemiology and Prevention & Health Behavior and Outcomes programs
|
|
TRANSLATIONAL AND CLINICAL RESEARCH
|
|
Interdisciplinary collaborations between Basic Sciences, Cancer Control & Population Sciences, and Translational & Clinical Research members
|
|
Mody, R.; Yu, A. L.; Naranjo, A.; Zhang, F. F.; London, W. B.; Shulkin, B. L.; Parisi, M. T.; Servaes, S. E.; Diccianni, M. B.; Hank, J. A.; Felder, M.; Birstler, J.; Sondel, P. M.; Asgharzadeh, S.; Glade-Bender, J.; Katzenstein, H.; Maris, J. M.; Park, J. R.; Bagatell, R.
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
J Clin Oncol
(2020) :JCO2000203. PMID: 32343642.
|
|
|
Lead study author Rajen Mody, M.D., M.S.
|
|
"
In a first of its kind, international phase 2 trial of combination chemo-immunotherapy for relapsed/refractory high-risk neuroblastoma,
(HR-NBL), our team was able to show a robust synergy between anti-GD2 immunotherapy and chemotherapy with excellent clinical activity and with relatively good safety profile.
" -
Rajen Mody, M.D., M.S.
|
|
|
|
COLLABORATIVE PUBLICATIONS
|
|
Interdisciplinary collaborations between Basic Sciences, Cancer Control & Population Sciences, and Translational & Clinical Research members
|
|
Lanfranca, M. P.; Zhang, Y.; Girgis, A.; Kasselman, S.; Lazarus, J.; Kryczek, I.; Delrosario, L.; Rhim, A.; Koneva, L.; Sartor, M.; Sun, L.; Halbrook, C.; Nathan, H.; Shi, J.; Crawford, H. C.; Pasca di Magliano, M.; Zou, W.; Frankel, T. L.
Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice
.
Gastroenterology
(2020) 158:1417-1432.e11. PMID: 31843590.
|
|
|
We want to hear your feedback!
|
|
Please forward this message to your colleagues.
|
|
|
|
|
|
|
